Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOCUS: Losartan/Hydrochlorothiazide Single-Pill Combination in Hypertension
NCT03946514Phase 4Completed
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Sep 2018
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in hypertension (HTN) comparing Losartan/HCTZ Group with Amlodipine/HCTZ Group (2 arms). Primary endpoints: Adverse events at 8 weeks and Blood pressure control rate at 8 weeks. Started Sep 2018; status: completed.
02
Drugs
losartanhydrochlorothiazide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03946514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03946514.